Patents by Inventor Yiguang Wang
Yiguang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200202428Abstract: A graphical structure model trained by using labeled samples is obtained. The graphical structure model is defined based on an enterprise relationship network that includes nodes and edges. Each labeled sample includes a label indicating whether a corresponding node is a risky credit node. The graphical structure model is configured to iteratively calculate an embedding vector of at least one node in a hidden feature space based on an original feature of the at least one node and/or a feature of an edge associated with the at least one node. An embedding vector corresponding to a test-sample is calculated by using the graphical structure model. Credit risk analysis is performed on the test-sample. The credit risk analysis is performed based on a feature of the test-sample represented in the embedding vector. A node corresponding to the test-sample is labeled as a credit risk node.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Applicant: Alibaba Group Holding LimitedInventors: Le Song, Hui Li, Zhibang Ge, Xin Huang, Chunyang Wen, Lin Wang, Tao Jiang, Yiguang Wang, Xiaofu Chang, Guanyin Zhu
-
Publication number: 20200202219Abstract: One or more implementations of the present specification provide risk control of transactions based on a graphical structure model. A graphical structure model trained by using labeled samples is obtained. The graphical structure model is defined based on a transaction data network that includes nodes representing entities in a transaction and edges representing relationships between the entities. Each labeled sample includes a label indicating whether a node corresponding to the labeled sample is a risky transaction node. The graphical structure model is configured to iteratively calculate an embedding vector of the node in a latent feature space based on an original feature of the node or a feature of an edge associated with the node. An embedding vector of an input sample is calculated by using the graphical structure model. Transaction risk control is performed on the input sample based on the embedding vector.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Applicant: Alibaba Group Holding LimitedInventors: Le Song, Hui Li, Zhibang Ge, Xin Huang, Chunyang Wen, Lin Wang, Tao Jiang, Yiguang Wang, Xiaofu Chang, Guanyin Zhu
-
Publication number: 20190093112Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).Type: ApplicationFiled: November 24, 2016Publication date: March 28, 2019Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.Inventors: Yiguang WANG, Yang JIANG, Xiaofeng ZHAO, Weiqing HE, Jianlu DAI
-
Publication number: 20190001160Abstract: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.Type: ApplicationFiled: December 5, 2016Publication date: January 3, 2019Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD .Inventors: Yiguang WANG, Yang JIANG, Xiaofeng ZHAO, Weiqing HE
-
Publication number: 20180369424Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.Type: ApplicationFiled: August 27, 2018Publication date: December 27, 2018Applicant: The Board of Regents of the University of Texas SystemInventors: Jinming GAO, Gang HUANG, Tian ZHAO, Xinpeng MA, Yiguang WANG, Yang LI, Baran D. SUMER
-
Patent number: 10098971Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.Type: GrantFiled: December 5, 2016Date of Patent: October 16, 2018Assignee: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, Gang Huang, Tian Zhao, Xinpeng Ma, Yiguang Wang, Yang Li, Baran D. Sumer
-
Publication number: 20180291134Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: ApplicationFiled: June 13, 2018Publication date: October 11, 2018Applicant: The Board of Regents of the University of Texas SystemInventors: Jinming GAO, David BOOTHMAN, Kejin ZHOU, Xiaonan HUANG, Yiguang WANG
-
Patent number: 10017598Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: GrantFiled: July 27, 2017Date of Patent: July 10, 2018Assignee: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, David Boothman, Kejin Zhou, Xiaonan Huang, Yiguang Wang
-
Publication number: 20170320993Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: ApplicationFiled: July 27, 2017Publication date: November 9, 2017Applicant: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, David BOOTHMAN, Kejin ZHOU, Xiaonan HUANG, Yiguang WANG
-
Patent number: 9751970Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: GrantFiled: March 17, 2016Date of Patent: September 5, 2017Assignee: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, David Boothman, Kejin Zhou, Xiaonan Huang, Yiguang Wang
-
Publication number: 20170143852Abstract: The present disclosure relates to polymers which contain a hydrophobic and hydrophilic segment which is sensitive to pH. In some aspects, the polymers form a micelle which is sensitive to pH and results in a change in fluorescence based upon the particular pH. In some aspects, the disclosure also provides methods of using the polymers for the imaging of cellular or extracellular environment or delivering a drug.Type: ApplicationFiled: December 5, 2016Publication date: May 25, 2017Inventors: Jinming GAO, Gang HUANG, Tian ZHAO, Xinpeng MA, Yiguang WANG, Yang LI, Baran D. SUMER
-
Publication number: 20160220706Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: ApplicationFiled: March 17, 2016Publication date: August 4, 2016Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Jinming Gao, David BOOTHMAN, Kejin ZHOU, Xiaonan HUANG, Yiguang WANG
-
Patent number: 8759032Abstract: A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, including the steps of: (a) constructing a recombinant plasmid including a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I-producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively including a single gene ist.Type: GrantFiled: July 21, 2011Date of Patent: June 24, 2014Assignee: Shen Yang Tonglian Group Co., Ltd.Inventors: Yiguang Wang, Yang Jiang, Shengwu Yang, Xiaofeng Zhao
-
Publication number: 20140023590Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.Type: ApplicationFiled: August 11, 2011Publication date: January 23, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Jinming Gao, David Boothman, Kejin Zhou, Xiaonan Huang, Yiguang Wang
-
Publication number: 20130130324Abstract: A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, comprising the steps of: (a) constructing a recombinant plasmid comprising a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I—producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively comprising a single gene ist.Type: ApplicationFiled: July 21, 2011Publication date: May 23, 2013Applicant: SHEN YANG TONGLIAN GROUP CO., LTD.Inventors: Yiguang Wang, Yang Jiang, Shengwu Yang, Xiaofeng Zhao